U.S. Stock Market Midday Update

Vor BioPharma, up 12.73%, with a year-to-date increase of 123.32%. Based on recent key news:

1. On June 27, Vor Bio announced a 95% workforce reduction, retaining only 8 employees for basic operations, and halted all clinical trials, seeking "strategic alternatives." This move raised market concerns about the company's future development, leading to stock price fluctuations.

2. On June 26, Rongchang Biotechnology entered into a licensing agreement with Vor Bio, granting Vor Bio exclusive rights to develop and commercialize globally, excluding Greater China. This news boosted market confidence, driving the stock price up.

3. On June 9, innovative drug concept stocks performed strongly, with Vor Bio benefiting from overall market sentiment, resulting in a stock price increase.

Stocks with High Trading Volume in the Industry

Celcuity rose 214.53%, with increased trading volume. Based on recent important news:

1. On July 28, Celcuity announced that its VIKTORIA-1 trial's PIK3CA wild-type cohort achieved clinically significant improvement in progression-free survival, planning to submit a new drug application to the FDA in the fourth quarter of 2025, causing the stock price to surge 114%.

2. On July 25, Celcuity announced the start of the VIKTORIA-2 clinical trial, with the first patient receiving treatment, and the market holds an optimistic outlook on its treatment prospects.

3. On July 25, Celcuity planned to hold a conference call on July 28 to announce the topline results of the VIKTORIA-1 trial, with investors expecting positive outcomes.

CervoMed rose 27.95%, with a trading volume of 113 million. Based on recent important news:

1. On July 28, CervoMed announced that its drug neflamapimod showed significant efficacy in patients with Lewy body dementia, with the stock price rising 49% in pre-market trading.

2. On July 28, CervoMed's interim trial data showed that neflamapimod reduced the risk of disease progression by 54%, leading to a 58.7% increase in stock price.

3. On July 28, CervoMed reported a significant reduction in GFAP levels in its trial, further enhancing market confidence.

Gilead Sciences fell 2%, with increased trading volume. Based on recent important news:

1. On July 25, EU regulators supported Gilead's HIV prevention drug lenacapavir, causing the stock price to rise 2.31%.

2. On July 26, Needham upgraded Gilead's rating to Buy, with a target price of $133, driving stock price fluctuations.

3. On July 25, analysts raised Yeztugo's revenue expectations to $6.3 billion, with a positive market reaction Stocks Ranked Among the Top by Market Capitalization in the Industry

AbbVie fell 0.81%, with increased trading volume. According to recent important news:

1. On July 25, MarketBeat pointed out that although AbbVie was rated as "Moderate Buy," top analysts were more optimistic about five other stocks, leading to a decline in market confidence and a drop in stock price.

2. On July 26, MarketBeat reiterated that AbbVie was not included in the list of top recommended stocks, further undermining investor confidence.

3. On July 27, retail trading volume surged, increasing market volatility, which affected AbbVie's stock performance